Ulteriori informazioni
Edited by three of the world s leading pharmaceutical scientists, this is the first book on this important and hot topic, containing much previously unpublished information. As such, it covers all aspects of green chemistry in the pharmaceutical industry, from simple molecules to complex proteins, and from drug discovery to the fate of pharmaceuticals in the environment. Furthermore, this ready reference contains several convincing case studies from industry, such as Taxol, Pregabalin and Crestor, illustrating how this multidisciplinary approach has yielded efficient and environmentally-friendly processes. Finally, a section on technology and tools highlights the advantages of green chemistry.
Info autore
Andy Wells is a Principal Scientist in the AstraZeneca Global Process R&D Group. Following a BSc and PhD at Essex University he joined Chemical Development at SmithKline & French in 1986, (SmithKline Beecham in 1989). Experienced in all aspects of organic synthesis and scale-up, he has special interests in chemo-catalysis, biocatalysis and green chemistry. Whilst at SmithKline Beecham he won a corporate Green Chemistry/Technology award in 1999. He currently leads the AstraZeneca Green Chemistry group and is co-chair of American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable. He is also on the international advisory board of the journal, ChemSusChem.
Michael Williams joined Pfizer in 1972 following his PhD with Professor Charles Rees (University of Liverpool), and rose to become Executive Director and Departmental Head of UK Chemical R&D in 2003. His mid-career responsibilities included the Medicinal Chemistry interface, outsourcing initiatives and technology adoption. In addition to his experience with about 50 early drug candidates, he played a significant role in the late development, filing and commercialization of many agents including ZoloftTM, ViagraTM and RelpaxTM. Since retiring from Pfizer in late 2007, he has become an independent CMC consultant.
Riassunto
Von drei weltbekannten Pharmazeuten herausgegeben, widmet sich dieser Band erstmals der "grünen" Chemie im Umfeld der pharmazeutischen Industrie. Dabei geht es um einfache kleine Moleküle genauso wie um komplexe Proteine, um pharmazeutische Grundlagenforschung und um das Schicksal von Wirkstoffen in der Umwelt. Die handliche Monographie enthält zahlreiche bisher nicht publizierte Informationen, dazu überzeugende Fallstudien aus der Industrie (Taxol, Pregabalin, Crestor etc.), die zeigen, inwieweit ein multidisziplinärer Ansatz Effizienz und Umweltfreundlichkeit der Prozesse befördern kann. Ein abschließendes Kapitel befasst sich mit eindrucksvollen Technologien und technischen Hilfsmitteln.
Relazione
"At last! A book which looks at Green Chemistry from an industrial viewpoint! This is the best book I have read on Green Chemistry and should be on the bookshelf of every process chemist and engineer. Outstanding!" ( Organic Process Research & Development , March 2010)
